Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 14;13(12):2508. doi: 10.3390/v13122508

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

6MMPr increases the favipiravir antiviral potency against IAV (H1N1) and HCoV-OC43. (A) HCoV-OC43 titer of supernatants collected 72 hpi from Huh7 cells inoculated at MOI of 0.1 and treated with different concentrations of FAV in combination with 6MMPr or DMSO. Bars depict the mean ± SEM from two independent experiments conducted in duplicate. (B) The 3D plot indicating synergistic antiviral effect. (C) Cytopathic effects (CPE) induced by IAV in Huh7 cells inoculated at MOI of 0.2 and treated with increasing concentrations of favipiravir (FAV) in combination with 0.1 µM 6MMPr (red bars) or DMSO (0 µM, blue bars) for 48 hpi. The bars represent mean CPE normalized vs. DMSO-treated cells ± SEM of three independent experiments. *, p < 0.05; ***, p < 0.001. (D) The 3D plot indicating synergistic antiviral effect. Total volume of synergy = TVS, calculated at 99.9% confidence interval.